Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
Poll|Poll|March 9, 2015
Abnormality in Young Patient Discovered on Imaging
Author(s)Cesar A. Moran, MD
A 20-year-old man is found to have an abnormality on imaging. A biopsy is performed. What is your diagnosis?
Advertisement
A 20-year-old man is found to have an abnormality on imaging. A biopsy is performed.
What is your diagnosis?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5